

Kathleen K Christians

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1228664/publications.pdf>

Version: 2024-02-01

93
papers

1,512
citations

331670

21
h-index

330143

37
g-index

94
all docs

94
docs citations

94
times ranked

2240
citing authors

#	ARTICLE	IF	CITATIONS
1	Pancreatic ductal adenocarcinomas associated with intraductal papillary mucinous neoplasms (IPMNs) versus pseudo-IPMNs: relative frequency, clinicopathologic characteristics and differential diagnosis. <i>Modern Pathology</i> , 2022, 35, 96-105.	5.5	13
2	Reconstructing the tumor microenvironment to unlock therapeutic options in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 589-589.	1.6	1
3	Comprehensive genomic profiling (CGP) of fibrolamellar oncocytic hepatoma (FLO) and conventional hepatocellular carcinomas (HCC): An observational study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 474-474.	1.6	0
4	Targeted therapy (TT) in patients with KRAS wildtype (WT) pancreatic ductal adenocarcinoma (PDAC) produces durable response.. <i>Journal of Clinical Oncology</i> , 2022, 40, 596-596.	1.6	0
5	Palliative Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis: Is It Safe and Effective?. <i>Journal of Surgical Research</i> , 2022, 278, 31-38.	1.6	1
6	MEK-inhibitor (inh) and hydroxychloroquine (HCQ) in <i>KRAS</i> -mutated advanced pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, e16260-e16260.	1.6	2
7	Neoadjuvant radiation case volume and associated with margin-negative resection rates in patients with pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16281-e16281.	1.6	0
8	Total Neoadjuvant Therapy for Operable Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2246-2256.	1.5	29
9	Impact of KRAS alterations in localized pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 431-431.	1.6	0
10	Impact of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4136-4136.	1.6	1
11	Clinical outcomes in pancreatic ductal adenocarcinoma (PDAC) patients with underlying autoimmune disease (AID).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16233-e16233.	1.6	0
12	Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Index neighborhoods. <i>American Journal of Surgery</i> , 2021, 222, 10-17.	1.8	41
13	Pancreaticoduodenectomy and Vascular Reconstruction. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 731-746.	1.5	4
14	Two-Stage Hepatectomy for Bilateral Colorectal Liver Metastases: A Multi-institutional Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 1457-1465.	1.5	17
15	Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 879-889.	5.9	2
16	Primary Liver Cancer: An NCDB Analysis of Overall Survival and Margins After Hepatectomy. <i>Annals of Surgical Oncology</i> , 2020, 27, 1156-1163.	1.5	7
17	Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 235-242.	1.7	6
18	Commentary: Venous resection and reconstruction at the time of pancreatectomy for cancer. <i>Surgery</i> , 2020, 168, 1058-1059.	1.9	1

#	ARTICLE	IF	CITATIONS
19	Variant anatomy of the biliary system as a cause of pancreatic and peri-ampullary cancers. <i>Hpb</i> , 2020, 22, 1675-1685.	0.3	10
20	High neutrophil-lymphocyte ratio is not independently associated with worse survival or recurrence in patients with extremity soft tissue sarcoma. <i>Surgery</i> , 2020, 168, 760-767.	1.9	2
21	Locally advanced pancreatic cancer: staging, operability, and the importance of multimodality therapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 497-500.	1.5	3
22	Intraductal papillary squamous neoplasm of the pancreas: Cyto-histologic correlation of a novel entity. <i>Annals of Diagnostic Pathology</i> , 2020, 48, 151583.	1.3	1
23	Comparison of overall survival in gallbladder carcinoma at academic versus community cancer centers: An analysis of the National Cancer Data Base. <i>Journal of Surgical Oncology</i> , 2020, 122, 176-182.	1.7	7
24	Gross tumor size using the AJCC 8th ed. T staging criteria does not provide prognostic stratification for neoadjuvant treated pancreatic ductal adenocarcinoma. <i>Annals of Diagnostic Pathology</i> , 2020, 46, 151485.	1.3	6
25	Outcomes of palliative intent surgery in retroperitoneal sarcoma Results from the US Sarcoma Collaborative. <i>Journal of Surgical Oncology</i> , 2020, 121, 1140-1147.	1.7	7
26	Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 460.	2.8	20
27	Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. <i>Hpb</i> , 2020, 22, 1745-1752.	0.3	2
28	Utilization of somatic comprehensive genomic profiling (CGP) to identify patients (pts) with pancreatic cancer (PC) that harbor germline DNA damage repair (DDR) gene alterations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 760-760.	1.6	0
29	Impact of CDKN2A/b status in pancreatic cancer (PC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 759-759.	1.6	0
30	Outcomes of Elderly Patients Undergoing Curative Resection for Retroperitoneal Sarcomas: Analysis From the US Sarcoma Collaborative. <i>Journal of Surgical Research</i> , 2019, 233, 154-162.	1.6	6
31	Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. <i>Surgery</i> , 2019, 166, 277-285.	1.9	40
32	RAS Mutation Status Confers Prognostic Relevance in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer. <i>Journal of Surgical Research</i> , 2019, 240, 130-135.	1.6	13
33	Distal splenorenal and mesocaval shunting at the time of pancreatectomy. <i>Surgery</i> , 2019, 165, 298-306.	1.9	14
34	Effect of Donor Race-Matching on Overall Survival for African-American Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma. <i>Journal of the American College of Surgeons</i> , 2019, 228, 245-254.	0.5	8
35	Elective Regional Therapy Treatment for Hepatic Adenoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 125-130.	1.5	10
36	A randomized, phase II clinical trial of preoperative stereotactic body radiation therapy versus conventionally fractionated chemoradiation for resectable, borderline-resectable, or locally advanced type a pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4167-TPS4167.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Ablation approach for primary liver tumors: Perioperative outcomes. Journal of Surgical Oncology, 2018, 117, 1493-1499.	1.7	5
38	Minimally invasive hepatectomy conversions: an analysis of risk factors and outcomes. Hpb, 2018, 20, 132-139.	0.3	23
39	Locally advanced pancreas cancer: Staging and goals of therapy. Surgery, 2018, 163, 1053-1062.	1.9	53
40	Gallbladder carcinoma: An analysis of the national cancer data base to examine hispanic influence. Journal of Surgical Oncology, 2018, 117, 1664-1671.	1.7	4
41	Overall survival after resection of retroperitoneal sarcoma at academic cancer centers versus community cancer centers: An analysis of the National Cancer Data Base. Surgery, 2018, 163, 318-323.	1.9	29
42	Characterizing indeterminate liver lesions in patients with localized pancreatic cancer at the time of diagnosis. Abdominal Radiology, 2018, 43, 351-363.	2.1	11
43	The effect of prior upper abdominal surgery on outcomes after liver transplantation for hepatocellular carcinoma: An analysis of the database of the organ procurement transplant network. Surgery, 2018, 163, 1028-1034.	1.9	8
44	External radiation or ablation for solitary hepatocellular carcinoma: A survival analysis of the SEER database. Journal of Surgical Oncology, 2017, 116, 307-312.	1.7	21
45	A Novel Reconstruction Technique During Pancreaticoduodenectomy After Roux-En-Y Gastric Bypass: How I do It. Journal of Gastrointestinal Surgery, 2017, 21, 1186-1191.	1.7	3
46	Retroperitoneal lymphangiomyoma with lymph node involvement: A pathologic-radiologic correlation of a rare form of myomelanocytic tumor. Annals of Diagnostic Pathology, 2017, 27, 69-73.	1.3	3
47	Should functional renal scans be obtained prior to upper abdominal IMRT for pancreatic cancer?. Practical Radiation Oncology, 2017, 7, e449-e455.	2.1	0
48	The prognostic utility of baseline alpha-fetoprotein for hepatocellular carcinoma patients. Journal of Surgical Oncology, 2017, 116, 831-840.	1.7	27
49	Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. Hpb, 2017, 19, 659-666.	0.3	84
50	Palliative interventions for hepatocellular carcinoma patients: analysis of the National Cancer Database. Annals of Palliative Medicine, 2017, 6, 26-35.	1.2	15
51	Two-stage hepatectomy for colorectal liver metastases: A multi-institutional retrospective review.. Journal of Clinical Oncology, 2017, 35, 351-351.	1.6	0
52	Should functional renal scans be obtained prior to upper abdominal radiation for pancreatic cancer?. Journal of Clinical Oncology, 2017, 35, 442-442.	1.6	0
53	Does hepatectomy approach influence transfusion? An analysis of the National Surgical Quality Improvement Program database.. Journal of Clinical Oncology, 2017, 35, 447-447.	1.6	0
54	Minimally invasive hepatectomy conversions: An analysis of outcomes.. Journal of Clinical Oncology, 2017, 35, 430-430.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Impact of age on genomic alterations associated with pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 282-282.	1.6	0
56	Prognostic value of positron emission tomography and preoperative CA19-9 in patients treated on a prospective phase II trial of neoadjuvant therapy and surgery.. Journal of Clinical Oncology, 2017, 35, e15766-e15766.	1.6	0
57	Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. Journal of Oncology Practice, 2016, 12, 915-923.	2.5	19
58	Gallbladder Volvulus in a Patient with Type I Choledochal Cyst: A Case Report and Review of the Literature. Case Reports in Surgery, 2016, 2016, 1-6.	0.4	6
59	Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?. Journal of Surgical Oncology, 2016, 114, 581-586.	1.7	23
60	Techniques of Vascular Resection and Reconstruction in Pancreatic Cancer. Surgical Clinics of North America, 2016, 96, 1351-1370.	1.5	39
61	Replaced gastroduodenal artery: Added benefit of the "artery first" approach during pancreaticoduodenectomy" A case report. International Journal of Surgery Case Reports, 2016, 23, 93-97.	0.6	9
62	Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery, 2016, 159, 893-900.	1.9	114
63	Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine + nab-paclitaxel (NabG).. Journal of Clinical Oncology, 2016, 34, 397-397.	1.6	5
64	Can the sequence of chemotherapy regimens influence outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)?. Journal of Clinical Oncology, 2016, 34, 428-428.	1.6	2
65	Palliative care for hepatocellular carcinoma: Analysis of the National Cancer Data Base.. Journal of Clinical Oncology, 2016, 34, 390-390.	1.6	0
66	Rapid immunohistochemical analysis of pancreatic cytology from endoscopic ultrasound-guided fine-needle aspirates: A prospective clinical trial.. Journal of Clinical Oncology, 2016, 34, 400-400.	1.6	0
67	Overall survival and resection margin after hepatectomy for intrahepatic cholangiocarcinoma at academic cancer centers versus community cancer centers.. Journal of Clinical Oncology, 2016, 34, 339-339.	1.6	0
68	Can response to treatment predict outcome in patients with metastatic pancreatic adenocarcinoma (MPAC)?. Journal of Clinical Oncology, 2016, 34, 443-443.	1.6	31
69	Radiotherapy for intrahepatic cholangiocarcinoma: An analysis of the National Cancer Database.. Journal of Clinical Oncology, 2016, 34, 379-379.	1.6	0
70	Surgical resection versus ablation for hepatocellular carcinoma "Acm: a population-based analysis. Hpb, 2015, 17, 896-901.	0.3	34
71	Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy. Hpb, 2015, 17, 1119-1123.	0.3	10
72	Additional Support for Neoadjuvant Therapy in the Management of Pancreatic Cancer. Annals of Surgical Oncology, 2015, 22, 1755-1758.	1.5	7

#	ARTICLE	IF	CITATIONS
73	Chemotherapy for Surgically Resected Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 3716-3723.	1.5	83
74	Palliative Care Training in Surgical Oncology and Hepatobiliary Fellowships: A National Survey of Program Directors. <i>Annals of Surgical Oncology</i> , 2015, 22, 1181-1186.	1.5	23
75	Chemotherapy for surgically resected intrahepatic cholangiocarcinoma: Influence of lymph node status on treatment efficacy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 353-353.	1.6	0
76	Neoadjuvant FOLFIRINOX for Borderline Resectable Pancreas Cancer: A New Treatment Paradigm?. <i>Oncologist</i> , 2014, 19, 266-274.	3.7	183
77	Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 41-46.	0.6	44
78	Arterial resection at the time of pancreatectomy for cancer. <i>Surgery</i> , 2014, 155, 919-926.	1.9	94
79	Neoadjuvant therapy for pancreatic cancer in patients older than age 75.. <i>Journal of Clinical Oncology</i> , 2014, 32, 287-287.	1.6	8
80	Molecular profiling in gastric cancer: Examining potential targets for chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 131-131.	1.6	0
81	Critical steps for pancreaticoduodenectomy in the setting of pancreatic adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2013, 107, 33-38.	1.7	38
82	Duplicate pancreas meets gastric duplication cyst: A tale of two anomalies. <i>International Journal of Surgery Case Reports</i> , 2013, 4, 735-739.	0.6	17
83	Distal splenorenal and temporary mesocaval shunting at the time of pancreatectomy for cancer: Initial experience from the Medical College of Wisconsin. <i>Surgery</i> , 2013, 154, 123-131.	1.9	49
84	Modern perspectives on factors predisposing to the development of gallbladder cancer. <i>Hpb</i> , 2013, 15, 839-844.	0.3	59
85	Association of decline in serum Ca19-9 after neoadjuvant therapy with improved survival among borderline resectable pancreatic cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15082-e15082.	1.6	2
86	Microwave ablation for hepatic malignancies: A multi-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 218-218.	1.6	1
87	Local control in resectable and borderline resectable pancreatic cancer (PCa) treated with preoperative chemoradiation using IMRT or chemotherapy alone.. <i>Journal of Clinical Oncology</i> , 2013, 31, 282-282.	1.6	0
88	Phase II clinical trial of biomarker-directed therapy for localized pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS4147-TPS4147.	1.6	1
89	5-FU/leucovorin, irinotecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14613-e14613.	1.6	9
90	Does a common vascular origin confer similar prognosis to malignant tumors of the liver?. <i>Journal of Clinical Oncology</i> , 2012, 30, 186-186.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Are we justified in excluding combined hepatocellular-cholangiocarcinoma from transplantation? Journal of Clinical Oncology, 2012, 30, 256-256.	1.6	0
92	Portal Vein Resection. Surgical Clinics of North America, 2010, 90, 309-322.	1.5	41
93	The use of recombinant activated factor VII in trauma-associated hemorrhage with crush injury. Journal of Trauma, 2005, 59, 742-6.	2.3	1